Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Raptor Pharmaceuticals Corp. (RPTP - Snapshot Report) recently announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has rendered a positive opinion on Procysbi (mercaptamine) for orphan medicinal product exclusivity for the treatment of proven nephropathic cystinosis.

We note that Raptor Pharma’s efforts to get the drug approved in the EU  for the indication is well on tack. In Jun 2013, the company received a positive opinion from the EMA’s European Committee for Medicinal Products for Human Use (CHMP) regarding the approval of Procysbi (25mg and 75mg) for the treatment of proven nephropathic cystinosis.

We remind investors that Procysbi was approved by the U.S. Food and Drug Administration (FDA) on Apr 30, 2013 for the treatment of nephropathic cystinosis in adults as well as in children above 6 years of age. The drug was launched last month. Moreover, Procysbi enjoys orphan drug status in the U.S. The  DESIGNATION will protect the drug for seven years from the date of approval.  Procysbi is the company’s only marketed product.

On receiving the US approval for Procysbi, Raptor Pharma received the second tranche of $25 million, under its loan agreement with HealthCare Royalty Partners (HC Royalty). In Dec 2012, the companies signed a loan agreement under which Raptor Pharma agreed to borrow $50 million for Procysbi. The first tranche of $25 million was received in Dec 2012. The loan is expected to mature in 2019.

Meanwhile, Raptor Pharma has an interesting pipeline. The key pipeline candidate at Raptor Pharma is RP103. A phase II/III trial evaluating RP103 for the treatment of Huntington’s disease in patients with cysteamine is ongoing. The company has received orphan drug designation from the FDA for RP103 for the Huntington’s disease indication. The candidate is also being studied under a phase IIb trial for the treatment of nonalcoholic fatty liver in children.

Raptor Pharma, a biopharma stock, presently carries a Zacks Rank #4 (Sell). Other biopharma stocks which look better positioned include Jazz Pharmaceuticals (JAZZ - Analyst Report), Sarepta Therapeutics, Inc. (SRPT - Snapshot Report) and Medivation, Inc. (MDVN - Analyst Report) with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%